Literature DB >> 20213095

Long-term interferon-α treatment suppresses tumor growth but promotes metastasis capacity in hepatocellular carcinoma.

Peng-Yuan Zhuang1, Ju-Bo Zhang, Wei Zhang, Xiao-Dong Zhu, Ying Liang, Hua-Xiang Xu, Yu-Quan Xiong, Ling-Qun Kong, Lu Wang, Wei-Zhong Wu, Zhao-You Tang, Lun-Xiu Qin, Hui-Chuan Sun.   

Abstract

PURPOSE: To elucidate the effect of IFN-α treatment on tumor growth and metastasis of hepatocellular carcinoma (HCC).
METHODS: IFN-α administration was conducted in nude mice using an orthotopic implantation model of human HCC, and the key molecular markers in the IFN-α treatment was detected by immunohistochemistry staining and PCR array.
RESULTS: Up to 12 weeks of IFN-α treatment significantly suppressed tumor growth of HCC, but relatively increased the number of circulating tumor cells, which might be due to the enhanced tumor hypoxia as well as up-regulation of metastasis-related genes, such as HIF-1α, c-met, u-PA, PDGF-A, and IL-8. However, IFN-α had no direct effect on migration and invasion of HCC cells.
CONCLUSIONS: IFN-α has janus face of consistently suppressing HCC growth, however, promoting tumor metastasis capacity, which is of clinical indication for the scientific administration of IFN-α and the similar antiangiogenesis drugs for their dual effect on tumor growth and metastasis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20213095     DOI: 10.1007/s00432-010-0848-1

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  44 in total

Review 1.  Hypoxia in cancer: significance and impact on clinical outcome.

Authors:  Peter Vaupel; Arnulf Mayer
Journal:  Cancer Metastasis Rev       Date:  2007-06       Impact factor: 9.264

Review 2.  Hypoxia and adaptive landscapes in the evolution of carcinogenesis.

Authors:  Robert J Gillies; Robert A Gatenby
Journal:  Cancer Metastasis Rev       Date:  2007-06       Impact factor: 9.264

3.  Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus.

Authors:  Yasushi Shiratori; Shuichiro Shiina; Takuma Teratani; Masatoshi Imamura; Shun'taro Obi; Shin'pei Sato; Yukihiro Koike; Haruhiko Yoshida; Masao Omata
Journal:  Ann Intern Med       Date:  2003-02-18       Impact factor: 25.391

4.  Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism.

Authors:  Gregory Bix; Remedios Castello; Michelle Burrows; Jason J Zoeller; Michelle Weech; Rex A Iozzo; Christopher Cardi; Mathew L Thakur; Christopher A Barker; Kevin Camphausen; Renato V Iozzo
Journal:  J Natl Cancer Inst       Date:  2006-11-15       Impact factor: 13.506

5.  Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.

Authors:  W Gregory Roberts; Pamela M Whalen; Erik Soderstrom; Garrett Moraski; Joseph P Lyssikatos; Huifen-F Wang; Beth Cooper; Deborah A Baker; Douglas Savage; Deepak Dalvie; James A Atherton; Sherry Ralston; Ruby Szewc; John C Kath; Jing Lin; Cathy Soderstrom; George Tkalcevic; Bruce D Cohen; Vince Pollack; Wayne Barth; Will Hungerford; Ethan Ung
Journal:  Cancer Res       Date:  2005-02-01       Impact factor: 12.701

6.  Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray.

Authors:  Y Li; Y Tang; L Ye; B Liu; K Liu; J Chen; Q Xue
Journal:  J Cancer Res Clin Oncol       Date:  2002-12-04       Impact factor: 4.553

7.  Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006).

Authors:  Danielle A Murphy; Sosina Makonnen; Wiem Lassoued; Michael D Feldman; Christopher Carter; William M F Lee
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

8.  Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules.

Authors:  Hiroaki Nagano; Atsushi Miyamoto; Hiroshi Wada; Hideo Ota; Shigeru Marubashi; Yutaka Takeda; Keizo Dono; Koji Umeshita; Masato Sakon; Morito Monden
Journal:  Cancer       Date:  2007-12-01       Impact factor: 6.860

9.  The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature.

Authors:  Bruce M Fenton; Scott F Paoni
Journal:  Cancer Res       Date:  2007-10-15       Impact factor: 12.701

10.  A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma.

Authors:  Chung Mau Lo; Chi Leung Liu; See Ching Chan; Chi Ming Lam; Ronnie T P Poon; Irene O L Ng; Sheung Tat Fan; John Wong
Journal:  Ann Surg       Date:  2007-06       Impact factor: 12.969

View more
  7 in total

1.  Isomalto oligosaccharide sulfate inhibits tumor growth and metastasis of hepatocellular carcinoma in nude mice.

Authors:  Chun-Li Xiao; Zhong-Hua Tao; Lin Guo; Wei-Wei Li; Jin-Liang Wan; Hui-Chuan Sun; Lu Wang; Zhao-You Tang; Jia Fan; Wei-Zhong Wu
Journal:  BMC Cancer       Date:  2011-04-22       Impact factor: 4.430

2.  Direct transformation of lung microenvironment by interferon-α treatment counteracts growth of lung metastasis of hepatocellular carcinoma.

Authors:  Peng-Yuan Zhuang; Jun Shen; Xiao-Dong Zhu; Ju-Bo Zhang; Zhao-You Tang; Lun-Xiu Qin; Hui-Chuan Sun
Journal:  PLoS One       Date:  2013-03-18       Impact factor: 3.240

3.  Tanshinone IIA inhibits metastasis after palliative resection of hepatocellular carcinoma and prolongs survival in part via vascular normalization.

Authors:  Wen-Quan Wang; Liang Liu; Hui-Chuan Sun; Yan-Ling Fu; Hua-Xiang Xu; Zong-Tao Chai; Qiang-Bo Zhang; Ling-Qun Kong; Xiao-Dong Zhu; Lu Lu; Zheng-Gang Ren; Zhao-You Tang
Journal:  J Hematol Oncol       Date:  2012-11-08       Impact factor: 17.388

4.  N-acetylcysteine improves antitumoural response of Interferon alpha by NF-kB downregulation in liver cancer cells.

Authors:  Nelson Alexandre Kretzmann; Eduardo Chiela; Ursula Matte; Norma Marroni; Claudio Augusto Marroni
Journal:  Comp Hepatol       Date:  2012-12-04

Review 5.  Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Liping Zhuang; Xiantao Zeng; Zongguo Yang; Zhiqiang Meng
Journal:  PLoS One       Date:  2013-09-17       Impact factor: 3.240

6.  Higher proliferation of peritumoral endothelial cells to IL-6/sIL-6R than tumoral endothelial cells in hepatocellular carcinoma.

Authors:  Peng-Yuan Zhuang; Jian-Dong Wang; Zhao-Hui Tang; Xue-Ping Zhou; Zhi-Wei Quan; Ying-Bin Liu; Jun Shen
Journal:  BMC Cancer       Date:  2015-11-02       Impact factor: 4.430

7.  Effect of TALEN-mediated IL-6 knockout on cell proliferation, apoptosis, invasion and anti-cancer therapy in hepatocellular carcinoma (HCC-LM3) cells.

Authors:  Peng-Yuan Zhuang; Ke-Wei Zhang; Jian-Dong Wang; Xue-Ping Zhou; Ying-Bin Liu; Zhi-Wei Quan; Jun Shen
Journal:  Oncotarget       Date:  2017-09-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.